Clinical trial · Interventional
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
A Phase I/II Study of Aroplatin™ in Patients With Advanced Solid Malignancies
NCT00057395CI-TRIAL-00000027unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Esophageal Neoplasms | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aroplatin (Liposomal NDDP, L-NDDP) | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced solid malignancies; * Amenable to therapy with DACH platinum agents; * Measurable disease (RECIST criteria); * ECOG performance score of 0-2; * Adequate hematopoietic, liver and renal function; * Adequate cardiac function (maximum of class II, NYHA); * Women of childbearing potential must have a negative urine or serum pregnancy test; * Signed written informed consent; * Subjects must be willing to be followed during the course of treatment/observation and follow-up. Exclusion Criteria: * No other active malignancies; * No prior therapy with oxaliplatin; * No known brain metastases; * Active, uncontrolled infection or other serious medical illnesses; * Not using or have used any investigational therapy during four weeks before start of protocol treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.